Continue using paclitaxel-eluting PAD devices

This week's top stories in cardiology:

1. FDA Panel: Continue using paclitaxel-eluting PAD Devices, with caveats. 
   
   Although the benefits of the devices were clear, the panel felt there should be a label change to warn of the late mortality signal seen in a key meta-analysis.

2. Many cardiac cath, electrophysiology lab directors receive big industry payments

   These payments were substantially higher than those made to local interventional cardiologists and electrophysiologist.

3. Two trials support shorter DAPT

   DAPT with a twist: Continuing the P2Y12 inhibitor instead of aspirin.

4. Do black patients with type 2 diabetes gain cardiac benefit from the SGLT2 and GLP-1 drugs?

   New findings suggest there is no effect on cardiovascular outcomes, although the analysis has limitations